360Medlink
Successful Digital Platforms for Clinical Trials Performance

COVID-19 has indeed been a “digital accelerant” for the healthcare industry. For pharmaceutical companies, the pandemic has marked the dawn of a new era of digital clinical trials. The crisis has shrunk timelines for the often decades-long digital transformation roadmaps of sponsors and contract research organizations and compelled them to adopt more digital, interactive, and remote ways of conducting clinical trials. However, while there are numerous clinical trial platforms existing in the market, most of them do not effectively collaborate or interact with each other. A clinical trial process is highly complex and entails multiple stakeholders and companies that provide technologies to monitor the trials, manage the drug delivery, handle the logistics, and deliver the drugs or devices required for the trials. This often leads to an environment of confusion, lack of coordination and clarity, communication siloes, and difficulty in aligning solutions with the needs of clients. Perfectly poised to address these challenges is 360Medlink—a software development company with a variety of successful digital platforms for clinical trials that bring considerable value to healthcare companies, particularly big pharma, biotech companies and agencies involved in clinical study services. Trusted by leading global pharmaceutical and other healthcare organizations, 360Medlink, with its suite of DHaaS (Digital Health as Service) platforms, is dedicated to building patient-centered solutions for healthcare organizations and the pharmaceutical industry.

Since 2010, 360Medlink has been developing clinical trial digital platforms to meet the needs of its B2B clients and end-users, and improve the performance of numerous trials, facilitate enrolment, and help coordinators reach recruitment goals. “Our cost-effective platforms allow clinical trial managers to easily communicate about the trials, share, promote and engage more with the investigator community both locally and internationally. We can quickly adapt to a client’s needs and help them complete their trials on schedule,” says Jean-Manassé Theagene, CEO and President at 360Medlink. “Considering our work with leading top20 global pharma and biotechs, to date, we count over a dozen commercialized pharma products that have previously benefited from our help to meet their phase- III trial objectives, especially in the areas of oncology and hematology.”

360Medlink offers TrialsAdvisorTM—a modular, fully customizable platform that provides a comprehensive overview of the clinical trials pipeline and clinical trials data in real-time. Moreover, the TrialsAdvisorTM mobile application has an interactive clinical search tool and easy to use interface, which enables field medical reps to effortlessly display the necessary information to the physicians.

In addition to showcasing numerous exciting features (pathways, cards, videos, maps, etc.), medical teams and field representatives (MSLs) can showcase the drug pipeline (compounds list) and all the trials associated with them through one powerful solution, making it easy and engaging to collaborate with healthcare professionals and potential investigators. The company offers private custom e-newsletters (TrialPressTM) to foster regular communication with investigators and improve engagement. The newsletters help with the effective mobilization of targeted investigators, whether local or international—a value-add for global trials. 360Medlink also providescTrialPortalsTM—a centralized, interactive, and personalized web platform to easily interact with an investigator community around specific clinical trial programs. The clinical trial web portal provides content tailored to the user’s interest and the selected disease area. As an engaging and scalable platform to communicate with investigators and healthcare professionals, cTrialPortalsTM increases investigators’ engagement, improves coordination, and significantly accelerates patient recruitment. Moreover, it’s cheap, efficient, and also quick to implement. “Our platforms (TrialsAdvisorTM, cTrialPortalsTM, and TrialPressTM) operate in synergy to be of service for any client involved in clinical trials. Our plug and play platforms are easily customizable and scalable, which enables any new client to seamlessly adapt our solutions as per their needs and roll out to the marketplace very rapidly,” states Dr. Ezzat S. Saad, Chief Medical Officer of the 360Medlink group. Based on the success of its product TAVIETM virtual coach (digital medicine in psoriasis, HIV and cancer) and the recent launch of CliniklyTM (digital care ecosystem, Data/Analytics and RWE), in the new post-COVID19 era, the company expects its strong portfolio of digital platforms which make it the partner of choice in the life sciences field.

Our cost-effective platforms allow clinical trial managers to easily communicate about the trials, share, promote and engage more with the investigator community both locally and internationally

360Medlink’s successful collaboration with various pharma and biotech companies of different sizes, healthcare organizations, and government agencies is a testament to its capabilities and innovation. Moreover, 360Medlink’s multi-expertise group is the backbone of the company, which comprises professionals with an extensive background in technology and medical practice, including physicians, nurses, and pharmacists. Theagene attributes his company’s success to its agility and innovation capacity. “Having an innovative technology is not enough. It’s also crucial to notice who delivers it, their relationship with clients, and how easily the solution can be adapted to a client’s needs. We bring in the right mix of technology, people, and processes to establish trust and credibility with our clients,” asserts Theagene.

Looking ahead, 360Medlink plans to grow its business and expand its strategic partnerships with other clinical trial related agencies, including CROs. “We plan to not only garner more clients but also enhance and expand our product offerings for our existing clients. We will continue to deliver on our promise of providing affordable and easily scalable clinical platforms adapted for healthcare transformation,” says Theagene.